Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study

por Wedzicha, Jadwiga A, Zhong, Nanshan, Ichinose, Masakazu, Humphries, Michael, Fogel, Robert, Thach, Chau, Patalano, Francesco, Banerji, Donald
Publicado 2017

LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD

por Zhong, Nanshan, Wang, Changzheng, Zhou, Xiangdong, Zhang, Nuofu, Humphries, Michael, Wang, Linda, Thach, Chau, Patalano, Francesco, Banerji, Donald
Publicado 2015

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study

por Vogelmeier, Claus F, Chapman, Kenneth R, Miravitlles, Marc, Roche, Nicolas, Vestbo, Jørgen, Thach, Chau, Banerji, Donald, Fogel, Robert, Patalano, Francesco, Olsson, Petter, Kostikas, Konstantinos, Wedzicha, Jadwiga A
Publicado 2018